Covaxin shows 81% efficacy, say ICMR and Bharat Biotech

Credit: IndiaTimes- Published on March 3, 2021
This interim efficacy trend puts Covaxin at par with other global front-runner vaccines, the desi vaccine’s co-developer, the Indian Council for Medical Research (ICMR), said in a statement. The results, evaluated by an independent data safety and monitoring board, show that the vaccine is well-tolerated and efficacious against...

Video credit: ANI
Published on March 3, 2021 -  01:42
'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech
Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial. "Today is an important day for us, country and Indian science. COVAXIN has demonstrated an interim vaccine efficacy of around 80.6% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR," Bharat Biotech chairman Dr Krishna Ella.

You are here


💡 newsR Knowledge: Other News Mentions

BBV152

Vaccine against COVID-19
The PM’s directive came at a review meeting on the Covid situation on Saturday a day after he had overseen an assessment of oxygen supplies and production and..
Credit: IndiaTimes - Published 9 hours ago

Union health minister Harsh Vardhan said financial support is being provided to four manufacturers to expand Covaxin vaccine production.
Credit: DNA - Published 1 day ago

The Union government on Friday said it will amp up the production of the indigenously developed Covaxin vaccine to 100 million doses per month by September. As..
Credit: IndiaTimes - Published 2 days ago


Bharat Biotech

Indian biotechnology company and vaccine manufacturer
Indications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and..
Credit: IndiaTimes - Published 1 week ago



You might like